jetcityimage/iStock Editorial by way of Getty Photographs Eli Lilly (NYSE:LLY) shares rose ~7% premarket Tuesday after the corporate elevated its full-year outlook above consensus, citing a robust efficiency in its weight reduction merchandise in Q1 2024. Whereas LLY’s quarterly earnings exceeded estimates, the corporate underperformed in income as gross sales from its diabetes remedy Trulicity…
